| [1] |
Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer[J]. Int J Mol Sci, 2019, 20(5): 1115.
|
| [2] |
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy[J]. Nat Rev Clin Oncol, 2021, 18(6): 327-344.
|
| [3] |
Norsworthy KJ, Ko CW, Lee JE, et al. FDA Approval Summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia[J]. Oncologist, 2018, 23(9): 1103-1108.
|
| [4] |
Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates[J]. Nat Rev Drug Discov, 2017, 16(5): 315-337.
|
| [5] |
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
|
| [6] |
Joubert N, Beck A, Dumontet C, et al. Antibody-drug conjugates: the last decade[J]. Pharmaceuticals (Basel), 2020, 13(9): 245.
|
| [7] |
Nakada T, Sugihara K, Jikoh T, et al. The Latest research and development into the antibody-drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy[J]. Chem Pharm Bull (Tokyo), 2019, 67(3): 173-185.
|
| [8] |
Yao X, Jiang J, Wang X, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity[J]. Breast Cancer Res Treat, 2015, 153(1): 123-133.
|
| [9] |
国家药品监督管理局. 国家药监局附条件批准注射用维迪西妥单抗上市[EB/OL][2021-06-09].
URL
|
| [10] |
Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer[J]. Nat Rev Clin Oncol, 2020, 17(1): 33-48.
|
| [11] |
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
|
| [12] |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360.
|
| [13] |
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006, 355(26): 2733-2743.
|
| [14] |
Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149.
|
| [15] |
Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J]. N Engl J Med，2020, 382(7):610-621.
|
| [16] |
Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117.
|
| [17] |
Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.
|
| [18] |
Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines®insights: breast cancer, version 4.2023[J]. J Natl Compr Canc Netw, 2023, 21(6): 594-608.
|
| [19] |
Yan M, Bian L, Hu X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study[EB/OL].[2023-01-20].
URL
|
| [20] |
Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
|
| [21] |
Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
|
| [22] |
Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J]. Gastric Cancer, 2021, 24(4): 913-925.
|
| [23] |
Zhang J, Liu R, Gao S, et al. Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours[J]. NPJ Breast Cancer, 2023, 9(1): 28.
|
| [24] |
中国抗癌协会国际医疗与交流分会，中国医师协会肿瘤医师分会乳腺癌学组. 人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版) [J]. 中华肿瘤杂志，2022, 44(12): 1288-1295.
|
| [25] |
Steuer CE, Hayashi H, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations[J]. J Clin Oncol, 2022, 40: 9017.
|
| [26] |
Haikala HM, Jänne PA. Thirty years of HER3: from basic biology to therapeutic interventions[J]. Clin Cancer Res, 2021, 27(13): 3528-3539.
|
| [27] |
Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
|
| [28] |
Shastry M, Jacob S, Rugo HS, et al. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer[J]. Breast, 2022, 66: 169-177.
|
| [29] |
Rugo HS, Bardia A, Tolaney SM, et al. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer[J]. Future Oncol, 2020, 16(12): 705-715.
|
| [30] |
Lorusso D, Vergote I, O’Cearbhaill RE, et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205[J]. J Clin Oncol, 2022, 40:5507.
|
| [31] |
Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182.
|
| [32] |
Hafeez U, Parakh S, Gan HK, et al. Antibody-drug conjugates for cancer therapy[J]. Molecules, 2020, 25(20): 4764.
|
| [33] |
Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer[J]. Cancer Discov, 2021, 11(10): 2436-2445.
|
| [34] |
Fuentes-Antrás J, Genta S, Vijenthira A, et al. Antibody-drug conjugates: in search of partners of choice[J]. Trends Cancer, 2023, 9(4): 339-354.
|
| [35] |
Cortés J, Diéras V, Lorenzen S, et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial[J]. JAMA Oncol, 2020, 6(8): 1203-1209.
|
| [36] |
Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol, 2020, 21(10): 1283-1295.
|
| [37] |
Chew BH, Vos RC, Stellato RK, et al. Diabetes-related distress and depressive symptoms are not merely negative over a 3-year period in malaysian adults with type 2 diabetes mellitus receiving regular primary diabetes care[J]. Front Psychol, 2017, 8: 1834.
|
| [38] |
Shim H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations[J]. Biomolecules, 2020, 10(3): 360.
|
| [39] |
Yamazaki CM, Yamaguchi A, Anami Y, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance[J]. Nat Commun, 2021, 12(1): 3528.
|
| [40] |
Ecaterina ID, Manish RS, Richard DC, et al. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors[J]. Cancer Res, 2021, 81 (4_Supplement): OT-03-02.
|
| [41] |
Subbiah V, Erwin W, Mawlawi O, et al. Phase I study of P-cadherin-targeted radioimmunotherapy with 90Y-FF-21101 monoclonal antibody in solid tumors[J]. Clin Cancer Res, 2020, 26(22): 5830-5842.
|